Share chart Iovance Biotherapeutics, Inc.
Extended chart
Simple chart
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc., биотехнологическая компания, работающая на клинической стадии, специализируется на разработке и коммерциализации продуктов иммунотерапии рака, чтобы использовать силу иммунной системы пациента для уничтожения раковых клеток. К основным кандидатам в продуктах компании относятся lifileucel, которая проходит II фазу клинических испытаний для лечения метастатической меланомы; и LN-145 для лечения метастатического рака шейки матки. more details| IPO date | 2010-10-15 |
|---|---|
| ISIN | US4622601007 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Див.доход ао | 0 |
| Сайт | https://www.iovance.com |
| Цена ао | 3.48 |
| Change price per day: | +4.46% (3.36) |
|---|---|
| Change price per week: | +14.71% (3.06) |
| Change price per month: | +2.03% (3.44) |
| Change price per 3 month: | -43.84% (6.25) |
| Change price per half year: | -68.18% (11.03) |
| Change price per year: | -69.85% (11.64) |
| Change price per 3 year: | -76.79% (15.12) |
| Change price per 5 year: | -87.99% (29.22) |
| Change price per 10 year: | -61.72% (9.17) |
| Change price per year to date: | -52.57% (7.4) |
|
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
|||||||||||||||||||||||||||||||||||||
| Institutions | Volume | Share, % |
|---|---|---|
| Vanguard Group Inc | 22812820 | 8.17 |
| MHR Fund Management, LLC | 19997103 | 7.16 |
| Blackrock Inc. | 19071756 | 6.83 |
| State Street Corporation | 16424388 | 5.88 |
| Perceptive Advisors LLC | 11979415 | 4.29 |
| Avoro Capital Advisors LLC | 6700000 | 2.4 |
| Pictet Asset Management Holding SA | 5263309 | 1.88 |
| Geode Capital Management, LLC | 5037098 | 1.8 |
| Artisan Partners Limited Partnership | 4827670 | 1.73 |
| Orbimed Advisors LLC. | 4707458 | 1.69 |
| ETF | Share, % | Profitability for 1 year, % | Dividends, % |
|---|---|---|---|
| Future Tech ETF | 0.29888 | 426.34 | 0.8416 |
| Principal Healthcare Innovators ETF | 0.29888 | 618.5 | 0.8416 |
| iShares Morningstar Small-Cap Growth ETF | 0.09458 | 596.94 | 0.72598 |
| iShares Morningstar Small-Cap ETF | 0.04826 | 391.25 | 1.60498 |
| 0.18 | 508.26 | 1 |
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Mr. Jean-Marc Bellemin M.B.A. | CFO, Principal Accounting Officer & Treasurer | 932.2k | 1972 (53 years) |
| Dr. Friedrich Graf Finckenstein M.D. | Chief Medical Officer | 1.06M | 1967 (58 years) |
| Ms. Sara Pellegrino | Vice President of Investor Relations & Public Relations | N/A | |
| Dr. Frederick G. Vogt Esq., J.D., Ph.D. | Interim CEO, President, General Counsel, Corporate Secretary & Director | 1.39M | 1974 (51 year) |
| Mr. Howard B. Johnson M.B.A. | Chief Business Officer | N/A | 1960 (65 years) |
| Dr. Igor P. Bilinsky Ph.D. | Chief Operating Officer | 1973 (52 years) | |
| Ms. Tracy Winton | Executive Vice President of Human Resources | ||
| Dr. Raj K. Puri M.D., Ph.D. | Executive VP of Regulatory Strategy & Translational Medicine | ||
| Mr. Brian Shew M.B.A. | Senior VP & Head of Digital and Information Technology | ||
| Mr. Kevin Smyth | Executive Vice President of Quality |
Address: United States, San Carlos, 999 Skyway Road - open in Google maps, open in Yandex maps
Website: https://www.iovance.com
Website: https://www.iovance.com
